HCMI Resources

As part of our pledge to elevate biological models, ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro models, including primary tissue-derived organoids.

ATCC has assembled a number of resources to help you get started culturing your next-generation cancer models. Explore the educational content below to learn more.

Posters

Propagation of human colon, mammary, and lung cancer organoids in growth medium utilizing tissue-specific reagent kits and ready-to-use Wnt-3a and R-Spondin1 conditioned media

Feasibility of Manufacturing-scale Bioproduction of Novel Next-generation 3D Organoid Cancer Models in Support of the Human Cancer Models Initiative

Universal Extracellular Matrix Supports Toxicology and Drug Screening in 2D and 3D Cell Culture Models from iPSC-derived Cells, Primary Cells, Engineered Lines, and Cancer Lines

Brochures

Human Cancer Models Initiative

Application Notes

Directed Differentiation Of Gastrointestinal Epithelial Organoids Using ATCC® Cellmatrix Basement Membrane From Multiple Human ATCC iPCS Lines (747KB/.pdf)

Protocol for the Thawing, Expansion, and Cryopreservation of Mouse Small Intestinal Organoids (2.34MB/.pdf)

Webinars

Next-generation cancer models from the Human Cancer Models Initiative

Protocols

Initiation, Expansion, and Cryopreservation of Human Primary Tissue-Derived Normal and Diseased Organoids in Embedded Three-Dimensional Culture

Freezing Organoid Cultures

Organoid Media 1A

Organoid Media 2A

Organoid Media 3A

Organoid Media 4A

Organoid Media 5A

Organoid Media 6A

Organoid Media 7A

Organoid Media 8A

Organoid Subculture

Organoid Thawing Protocol

External Link

Welcome Sanger Institute Cell Model Passports

HCMI is an international consortium dedicated to generating novel human tumor-derived culture models with associated genomic and clinical data. The HCMI consortium comprises funding agencies and cancer model development institutions. The consortium's funding agencies include the National Cancer Institute, Cancer Research UK, Hubrecht Organoid Technology, and Wellcome Sanger Institute. The current model development institutions include the Broad Institute and the Cold Spring Harbor Laboratory. The consortium provides these models and data as an open source. HCMI's goal is to create up to one thousand advanced cancer models from patient samples.